Loading...
homepage 2019-09-12T12:01:33+00:00

At the forefront of CAR-T, regenerative medicine, genomics and pharmaceutical research and development

healthcare from Boyalife

Health

Boyalife Health is comprised of the company’s diverse healthcare business, including automated cellular processing, stem cell banking, regenerative medicine, immune-oncology and anti-aging.

Boyalife Health
Genomics from Boyalife

Genomics

Located in Tianjin, Boyalife Genomics is a leading developer of animal embryo and animal cloning technologies that are used to help protect critically endangered species, to improve beef cattle yields for the Chinese market, and also to clone companion and highly-specialized service dogs.

Boyalife Genomics
Pharmaceutical from Boyalife

Pharma

Boyalife Pharmaceuticals is engaged in the research and development of innovative therapies addressing a broad range of disease areas, including central nervous system, cardiovascular, and cancer.

Boyalife Pharma
Boyalife Health
Boyalife Genomics
Boyalife Pharma

Car-TXpress

Car-TXpress animation

Boyalife’s cell processing affiliate, Cesca Therapeutics, is working to enter the rapidly-emerging CAR-T and immune-oncology space though development of CAR-TXpress™. CAR-TXpress, which is based on its proprietary AutoXpress platform technology, can facilitate the automated manufacture of high-quality, clinical-grade CAR-T cells at scale.

LEARN MORE

News

Boyalife’ Chairman Dr. Chris Xu Attend 2019 SAPA Healthcare Investment Forum & Roadshow

六月 15, 2019|

CAR-TXpress™ is Concerned by Academic Journal

五月 10, 2019|

Driving CAR-T Manufacture Optimization through Technology Innovation

二月 25, 2019|

Boyalife to Expand its CDMO Services into the Asia Pacific Region

三月 14, 2018|

Boyalife: Always Be a Practitioner of Public Responsibility

十二月 9, 2017|

Founded in 2009 as the International Consortium of Stem Cell Research (INCOSC), Boyalife Group is a privately-held global biopharmaceutical holding company with 30 subsidiaries and affiliated companies operating in three distinct business segments: 1) cellular processing and biobanking for regenerative medicine, CAR-T and other emerging immunotherapies, 2) genomics and 3) drug discovery. Boyalife Group is headquarted in Wuxi City, China, and maintains operations in Tianjin, Guangzhou, Beijing, Seoul, South Korea, New Delhi, India and Sacramento, California, USA. READ MORE

Boyalife - About Us

Founded in 2009 as the International Consortium of Stem Cell Research (INCOSC), Boyalife Group is a privately-held global biopharmaceutical holding company with 30 subsidiaries and affiliated companies operating in three distinct business segments: 1) cellular processing and biobanking for regenerative medicine, CAR-T and other emerging immunotherapies, 2) genomics and 3) drug discovery. Boyalife Group is headquarted in Wuxi City, China, and maintains operations in Tianjin, Guangzhou, Beijing, Seoul, South Korea, New Delhi, India and Sacramento, California, USA. READ MORE

Boyalife - About Us